Previous 10 | Next 10 |
Gainers: Big Rock Partners Acquisition (BRPA) +86%.Euro Tech Holdings (CLWT) +32%.Urban One (UONE) +28%.Sensei Biotherapeutics (SNSE) +28%.BBQ Holdings (BBQ) +22%.PDS Biotechnology (PDSB) +20%.Advanced Emissions Solutions (ADES) +19%.Progenity (PROG) +18%.Moxian (MOXC) +16%.Precipio (PRP...
Gainers: Precipio (PRPO) +23%, PDS Biotechnology (PDSB) +20%, Sensei Biotherapeutics (SNSE) +18%, Iovance Biotherapeutics (IOVA) +17%, Tyme Technologies (TYME) +12%.Losers: Black Diamond Therapeutics (BDTX) -30%, Aerpio Pharmaceuticals (A...
HOOKIPA Pharma ([[HOOK]] -7.1%) has sharply today after announcing an abstract that includes data for its lead assets HB-201 and HB-202 in advanced Human Papillomavirus 16-positive (HPV16+) cancers.The abstract will be part of an oral presentation scheduled for June 07 at the upcomi...
Data from first-in-human Phase 1 study of arenaviral therapeutics, including first data on HB-201/HB-202 alternating 2-vector therapy and expanded data on HB-201, to be featured as oral presentation Early dose escalation study will highlight antigen-specific CD8+ T cell data, anti...
Oncology programs advance with preliminary Phase 1 immunogenicity data showing robust antigen-specific CD8+ T cell response after one dose of HB-201 or HB-202; clinical results consistent with those observed in pre-clinical studies HOOKIPA on track to report additional HB-201 and ...
NEW YORK and VIENNA, Austria, May 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2021 financial ...
NEW YORK and VIENNA, Austria, April 29, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will parti...
NEW YORK and VIENNA, Austria, April 14, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will parti...
Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of circulating CD8+ T cells, after one dose of HB-201 or HB-202 Early data on HB-201 monotherapy show an increase in interferon-gamma and other immune stimulatory cytokines after a single...
Do You Have These Top Biotech Stocks On Your Watchlist? It goes without saying that the biotech sector remains a crucial aspect of the broader healthcare industry today. By extension, this would help explain why investors continue to watch the top biotech stocks . This would be ...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
A look at the top 10 most actives in the United States Longeveron Inc. (LGVN) rose 69.0% to $4.8499 on volume of 46,980,986 shares Virpax Pharmaceuticals Inc. (VRPX) rose 161.5% to $3.0333 on volume of 46,199,502 shares Maxeon Solar Technologies Ltd. (MAXN) fell 0.6% to $0.2464 on volume ...
2024-07-09 09:02:05 ET Hookipa Pharma Inc (HOOK) announced stock split at a ratio of 1-for-10 on 2024-07-10 ... Full story available on KlickAnalytics.com